Pharmaceuticals
Our global Pharmaceuticals portfolio includes more than 45 key marketed products, many of which are leaders in their respective therapeutic areas. We have received 17 new pharmaceutical product approvals in the US since 2000, the most of any pharmaceutical company.
Key pharmaceutical products marketed by Novartis are listed below by therapeutic area.
Click on the product link where available to display complete product information. Please note that some product links are intended for US residents only.
A-Z
A C D E F G L M N P R S T V X Z
Certican
Prevention of organ rejection
Coartem/ Riamet
Plasmodium falciparum malaria or mixed infections that include Plasmodium falciparum
Co-Diovan/Diovan HCT (valsartan and hydrochlorothiazide)
Hypertension
Visit www.diovan.com (US residents only)
Combipatch/Estalis
Treatment of symptoms of estrogen deficiency in postmenopausal women
Visit www.combipatch.com
Comtan
Parkinson’s disease
Visit www.comtan.com (US residents only)
Clozaril/ Leponex
Treatment-resistant schizophrenia
Visit www.clozaril.com (US residents only)
Cubicin (daptomycin)
Complicated skin and soft tissue infections (cSSTI), Right-sided endocarditis (RIE) due to Staphylococcus aureus, Staphylococcus aureus bacteremia when associated with RIE or cSSTI
Pharmaceuticals business at Novartis
Novartis discovers and develops innovative medicines with improved efficacy and fewer side-effects.
Latest news
Patient groups
Our commitment to high-quality healthcare has led to an enduring and trusted partnership between Novartis and various patient groups.